Creative Planning
SABS icon

Creative Planning’s SAB Biotherapeutics SABS Stock Holding History

Creative Planning’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-11,852
Closed -$20.8K – 4000
2025
Q2 		$20.8K Buy
+11,852
New +$19.6K ﹤0.01% 3593
2024
Q1 		– Sell
-4,752
Closed -$32.7K – 2996
2023
Q4 		$32.7K Hold
4,752
– – ﹤0.01% 2674
2023
Q3 		$29.9K Hold
4,752
– – ﹤0.01% 2545
2023
Q2 		$39.4K Hold
4,752
– – ﹤0.01% 2457
2023
Q1 		$20.9K Sell
4,752
-100
-2% -$633 ﹤0.01% 2404
2022
Q4 		$28.6K Buy
4,852
+100
+2% +$914 ﹤0.01% 2293
2022
Q3 		$33K Buy
4,752
+99
+2% +$983 ﹤0.01% 2150
2022
Q2 		$67K Hold
4,653
– – ﹤0.01% 2015
2022
Q1 		$175K Buy
+4,653
New +$215K ﹤0.01% 1916

Other funds holding SABS

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HWM
HB Wealth Management Atlanta, Georgia $15.5B AUM 18.35% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

Creative Planning's SABS Position: Q3 2025 in Review

Creative Planning sold out of SAB Biotherapeutics (SABS) in Q3 2025, closing a stake of 11,852 shares — an estimated $20.8K sold.

Creative Planning first reported a position in SABS in Q1 2022 and held it in 9 quarters. The position peaked at $175K in Q1 2022. 34 funds tracked by Wall St. Rank hold SABS as of Q3 2025.

  • Creative Planning reported no remaining SAB Biotherapeutics position as of Q3 2025 after selling out during the quarter.
  • Creative Planning sold 11,852 SAB Biotherapeutics shares in Q3 2025, an estimated $20.8K.
  • Creative Planning first reported a position in SAB Biotherapeutics in Q1 2022 and held it in 9 quarters.
  • Creative Planning's SAB Biotherapeutics position peaked at $175K in Q1 2022.
  • 34 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q3 2025.

Based on Creative Planning's 13F filing for Q3 2025, filed 14 Nov 2025.